Recent News & Events
(click on bold, green text for links)
|
Nov
1 |
Congratulations to our science team on their state of the science review of NLRP3 activation in cancer that describes the multiple roles of NLRP3 in several solid tumors. Dapansutrile and other specific NLRP3 inhibitors are referenced in the publication as potential therapeutic candidates for continued investigation. (see publication here).
|
|
June
22 |
Olatec’s publication in Journal of Neuroinflammation demonstrates that targeting the NLRP3 inflammasome by dapansutrile (OLT1177®), which crosses the blood brain barrier, reduces levels of α‑synuclein, protects dopaminergic neurons, improves locomotor function and could have the potential to become a safe and novel therapeutic approach that could arrest neuroinflammation and protect against neurological deficits of Parkinson’s disease in humans (see publication here). Additional studies supported by the Michael J. Fox Foundation are ongoing (see here)
|
|
|
|
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a grant from their Therapeutics Pipeline Program to support preclinical research evaluating Olatec Therapeutics’ lead compound, dapansutrile, in Parkinson’s disease (PD)
|
|
|
NEW YORK--(BUSINESS WIRE)--Olatec Therapeutics LLC (“Olatec” or the “Company”), a leader in developing NLRP3 inhibitors, announced the completion of the Company’s $40 million Series A round financing, the final closing of which was led by Sanders Morris Harris (“SMH”). Participation in the round came from both existing investors as well as new investors identified by each of Sanders Morris Harris, Advection Growth Capital and the Company. Proceeds will be principally used to advance Olatec’s lead compound, dapansutrile, into later stage clinical development.
|
|
(click on bold, green text for links)
|
Nov
16 |
Olatec CSO, Charles Dinarello to speak at UVA on the Past, Present and Future of IL-1
Olatec's CSO Charles Dinarello to speak at UVA tomorrow (11/17) at the RMB CVRC Seminar, hosted by SAB Member, Antonio Abbate: Past, Present and Future of Interleukin-1 in Human Disease. |
|
Nov
14 |
Olatec Data Presented at 2022 American College of Rheumatology Convergence
During a Scientific Session at the 2022 American College of Rheumatology Conference, entitled "Gout Is an Autoinflammatory Metabolic Disease", Michael Pillinger, Charles Dinarello and Naomi Schlesinger discuss the autoinflammatory nature of gout, demonstrating it as one of the truly IL-1 β -mediated diseases. They discuss research conducted in understanding the role NLRP3 inflammasome in gouty inflammation and review treatments of acute gout flares, including dapansutrile's clinical data. |
|
|
Nov
7 |
Jesús Amo Aparicio presents poster, "Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neuronsin a model of Parkinson’s disease” at 2022 Neuroscience Meeting
|
|
Aug
16 |
Craig T. Basson, MD, PhD Joins Olatec Therapeutics’ Board of Directors
NEW YORK--(BUSINESS WIRE)--Olatec Therapeutics LLC, a leader in the developing class of selective NLRP3 inhibitors, today announced that Craig T. Basson, MD, PhD has been elected to their Board of Directors. Excited to join Olatec’s Board of Directors, Dr. Basson explained: “I am thrilled to contribute to Olatec’s development of lead compound, dapansutrile – starting in gouty arthritis and to realize [dapansutrile’s] potential to translate the science of the NLRP3 inflammasome in multiple disease areas. I am confident in Olatec’s ultimate ability to deliver this important medicine globally to the many patients suffering from inflammatory diseases.”... |
|
|
May
7 |
Lars Lunding presents poster, "The NLRP3 Inflammasome Inhibitor OLT1177® Ameliorates Experimental Allergic Asthma in Mice” at 2022 Immunology Meeting
|
|
Apr
19 |
Olatec's Donation to the Ukranian People Received
We are pleased to report that the Ukrainian people in need of aid and medical supplies received our donation of certain OTC pain medication. We thank ABF Pharmaceutical Services GmbHfor their teamwork in this effort |
|
Mar
15 |
Mustafa Noor, MD, FACP, Joins Olatec as Chief Medical Officer
NEW YORK--(BUSINESS WIRE)--Olatec Therapeutics LLC, a leader in the developing class of selective NLRP3 inhibitors, today announced that Mustafa Noor, MD, FACP, joins the Company as Chief Medical Officer (CMO), following the decision of current CMO, Dr. Curt Scribner, to retire from the position. Dr. Noor remarked: “I believe this is a great time to be joining the Olatec team. I see Olatec at a major value inflection point and am excited to not only build on the world class translational science that has been elucidated, but help this exceptional team take dapansutrile through late-stage development and prospectively its approval in the lead indications.” Dr. Noor continued, “Olatec is at the forefront of a compelling new inflammation target across multiple disease areas, which creates many opportunities for dapansutrile and the OLT Analogue compounds.”... |
|
|
Feb
15 |
Olatec Announces High-Impact Coverage of Dapansutrile in Leading Journal on Cardiovascular Disease as well as Another Publication from New Preclinical Data in a Heart Failure Model
|
|
|
Oct
4-6 |
Olatec data from our preclinical studies using an Alzheimer’s disease model presented at Düsseldorf-Jülich Symposium on Neurodegenerative Diseases: Aggregates, Autophagy, Prions and Biomarkers on October 4-6, with Martin Korte PhD from TU Braunschweig, Germany presenting
|
|
Oct
4-5 |
Olatec data from our preclinical studies using an Alzheimer’s disease model presented at International Conference on Alzheimer’s Drug Discovery on October 4-5, with Niklas Lonnemann PhD candidate from TU Braunschweig, Germany presenting
|
|
Oct
1 |
Olatec data from our clinical Heart Failure trial and preclinical AMI studies, respectively, presented at Inflammasomes Symposium on October 1, hosted by Virginia Commonwealth University Center for Clinical and Translational Research with with Antonio Abbate MD (moderator), and Ben van Tassel MD and Stefano Toldo PhD from VCU presenting
|
|
Aug
24 |
Andrea Leonard-Segal, MD, FACR Joins Olatec’s Scientific Advisory Board and Becomes Medical Monitor in the Upcoming Gout Trial
NEW YORK--(BUSINESS WIRE)--Olatec Therapeutics LLC, a leader in the developing class of selective NLRP3 inhibitors, today announced that Andrea Leonard-Segal, MD, FACR joins the Company’s Scientific Advisory Board (SAB), and in tandem, assumes the role of Medical Monitor in the upcoming Phase 2b trial in the lead indication, acute gout flares... Continue Reading |
|
Jul
21 |
Gregory K. Palm Joins Olatec Therapeutics’ Board of Directors
NEW YORK--(BUSINESS WIRE)--Olatec Therapeutics LLC, a leader in the developing class of selective NLRP3 inhibitors, today announced that Gregory K. Palm, currently a senior advisor to The Goldman Sachs Group, has been elected to Olatec’s Board of Directors in connection with his making a substantial equity investment in the Company... Continue Reading |
|
Jul
8 |
Alberto Mantovani, MD Joins Olatec Therapeutics’ Scientific Advisory Board
NEW YORK--(BUSINESS WIRE)--Olatec Therapeutics LLC is very pleased to welcome Alberto Mantovani MD to its Scientific Advisory Board. Dr. Mantovani is world renown for his seminal work on the link between inflammation and cancer, demonstrating how a chronic inflammatory response promotes the development and metastasis of cancer. Dr. Mantovani's studies paved the way to change the view of the nature of cancer, from a tumor cell-centric focus, to one that includes the systemic role of immune cells as an essential component of neoplasia, i.e., abnormal growth of tumor cells. Dr. Mantovani's paradigm shift is now reflected in the development of immunotherapy for cancer, as currently approved... Continue Reading |
|
Apr
28 |
Olatec Therapeutics Announces Results Showing Dapansutrile Reduces Tumor Growth in a Mouse Model of Melanoma
NEW YORK-- (BUSINESS WIRE) -- Olatec Therapeutics LLC (Olatec) today announced the first publication from its preclinical studies with dapansutrile in selected cancer models. The data in this paper, entitled “Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion”, is published in the Proceedings of the National Academy of Sciences (PNAS). Under leading investigators including, Charles Dinarello MD, Olatec’s CSO, and Mayumi Fujita MD PhD, the data show that blocking NLRP3 with oral dapansutrile resulted in a significant reduction in tumor growth and progression when compared to untreated mice with induced melanoma...Continue Reading |
|
Apr
14 |
Denver Business Journal’s, Jensen Werley, reports on Olatec’s currently enrolling Phase 2 clinical trials in COVID-19 and its local partnership with leading respiratory center National Jewish Health. As reported, Olatec is enrolling patients in a Phase 2 clinical trial in the USA and Europe which is aimed at treating patients with its oral NLRP3 inhibitor, dapansutrile, early in the course of the disease to prevent progression into severe disease stages of inflammation requiring hospitalization. As added by Principal Investigator and pulmonologist at National Jewish Health, Dr. Michael Wechsler, in the Denver Business Journal, ‘it’s still important to have therapies available for those patients that do get sick with Covid-19’.
Click here to read article, Biotech company partners with National Jewish Health to test potential Covid-19 therapy for more. |
|
Apr
6 |
Olatec’s lead compound, dapansutrile, featured in "A Drug That Can Stop Tumors From Growing” published by Greg Glasgow at University of Colorado Anschutz Medical Campus. The article focuses on the positive results from our melanoma studies showing a reduction of tumor growth and progression. We congratulate Drs. Charles Dinarello, Mayumi Fujita, Carlo Marchetti, Isak Tengesdal, James DeGregori, Angelo D'Alessandro, Morkos Henen, Beat Vögeli, Eric Pietras.
|
|
Apr
1 |
Olatec referenced in "Pharma Looks to Inflammasome Inhibitors as All-Around Therapies”, an article published in The Scientist®.
|
|
February
26 |
Following the Marchetti et al study posted in bioRxiv, News Medical published, “NLRP3 inflammasome inhibitors may help treat early COVID-19, says study” which cites oral dapansutrile, specific NLRP3 inhibitor. This commentary makes the case for early NLRP3 inhibition which "might prevent the need for hospitalization and ease the enormous burden currently being placed on healthcare services"
|
|
February
24 |
Charles Dinarello MD, Carlo Marchetti PhD, Isak Tengesdal, William Janssen, Kara Mould posted a paper entitled “Targeting of the NLRP3 Inflammasome for early COVID-19” in bioRxiv .
In human plasma samples of patients newly infected with SARS-CoV-2, the data from the manuscript show NLRP3 activation leading to the production of the primary cytokine, IL-1β, early in the disease cycle. This paper further reinforces Olatec’s clinical trial (NCT04540120) with selective NLRP3 inhibitor, dapansutrile, in non-hospitalized patients with COVID-19 |
|
February
11 |
Olatec Therapeutics LLC Announces a Scientific Publication on the Positive Results in the First Known Clinical Trial with a Selective Oral NLRP3 Inhibitor, Dapansutrile, in Patients with Heart Failure
NEW YORK--(BUSINESS WIRE) -- Olatec Therapeutics LLC (Olatec) today announced the publication of the clinical data on its Phase 1b clinical study of patients with heart failure with reduced ejection fraction (HFrEF). Published in the Journal of Cardiovascular Pharmacology, the study met its primary objectives showing dapansutrile is safe and well tolerated in patients in all dose groups…Continue Reading |
|
December
29 |
Olatec Therapeutics’ Lead Compound, Dapansutrile, a Selective NLRP3 Inhibitor, Prevents the Inflammatory Response and Restores Cognitive and Behavioral Deficits in a Mouse Model of Alzheimer’s Disease
NEW YORK--(BUSINESS WIRE) -- Olatec Therapeutics LLC (“Olatec”) today announced the publication of data demonstrating the benefits of its selective NLRP3 inhibitor, dapansutrile, in a mouse model of Alzheimer’s Disease (AD). The data are published in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS). The study shows oral dosing with dapansutrile inhibits pathophysiological inflammatory processes, recovers significant cognitive losses and prevents neuroinflammation in the brains of transgenic mice induced with Alzheimer’s Disease (AD)…Continue Reading |
|
December
22 |
In the Journal of Medicinal Chemistry, Olatec is cited to have “presented phase II data for its compound dapansutrile in acute gout. This is, at the moment, the most clinically advanced NLRP3 inhibitor”, as stated in Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space
|
|
October
27 |
Olatec Enrolls its First Patients in a Phase 2 Placebo-Controlled Clinical Trial in COVID-19 with its Selective NLRP3 Inhibitor, Oral Dapansutrile
(New York, NY — October 27, 2020) Olatec Therapeutics LLC announced today that it is currently enrolling non-hospitalized COVID-19 patients with the aim to treat and prevent damaging effects of IL-1-induced inflammation that can lead to a fulminant Cytokine Storm. The trial is described as: “A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome.” … Continue Reading |
|
June
29 |
One of the world’s premier societies of cardiology, the European Society of Cardiology (ESC), accepted the abstract, “Safety of a novel oral NLRP3 inflammasome inhibitor, dapansutrile (OLT1177), in patients with stable heart failure with reduced ejection fraction” as a virtual poster at ESC’s 2020 Congress.
Olatec's poster presents the positive results of our Phase 1b Heart Failure Study, in which Dr. Antonio Abbate, leading cardiologist at Virginia Commonwealth University, was the Principal Investigator on the study. In his assessment of the study outcome, Dr. Abbate states, “We are all enthusiastic about the continued development of dapansutrile in cardiovascular disease and its clean safety profile. Dapansutrile's findings provide preliminary safety evidence and data for NLRP3 inhibition in patients who are expected to poorly tolerate side effects of NSAIDs or glucocorticoids." About ESC: ESC represents more than 95,000 professionals in the field of cardiology, focused on understanding the impact of cardiovascular disease and how we can better reduce its burden. |
|
June
23 |
A Frontiers in Immunology publication, entitled "Targeting the NLRP3 Inflammasome in Severe COVID-19”, underscores the validation of the NLRP3 target in treating cytokine release syndrome in COVID-19. Table 1 of the publication cites Olatec’s lead compound, dapansutrile, as the most advanced selective NLRP3 inhibitor in Phase 2 clinical trials in a broad spectrum of diseases.
|
|
June
19 |
Olatec’s CSO & SAB chair, Charles Dinarello MD announced as a joint winner of the 2020 Tang Prize in Biopharmaceutical Science for his groundbreaking achievements establishing IL-1β as a potent mediator of fever and inflammatory diseases.
“[Dinarello laid the groundwork for] the development of biopharmaceuticals that have benefited millions of people suffering from autoimmune and inflammatory diseases”, said the Tang Prize Foundation said today. The Tang Prize Foundation, established in 2012, awards its biannual prize across four categories, including scientists that aim to find a 21st century path to the sustainable development of the world. Link to article's here and here, and watch a video of Dr. Dinarello’s acceptance of the 2020 Tang Prize, where Charles documents his monumental discovery of IL-1β, a potent mediator of fever and inflammatory diseases. |
|
May
11 |
Reuters Health published, in Medscape, “Dapansutrile Appears Safe, Effective in Gout Patients”. The article quotes Dr. Michael H. Pillinger of NYU School of Medicine/NYU Langone Medical Center, “Now, thanks to a decade of advances in inflammation science, we understand the central role of the NLRP3 inflammasome, and of IL-1β in particular, in the pathogenesis of gout…This understanding has allowed the development of dapansutrile, which is likely destined to become the first agent designed specifically to treat gouty inflammation...”
|
|
Apr
23 |
Olatec’s NLRP3 inhibitor, dapansutrile, is cited in "Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease” in the Circulation Research, in which the publication stated, “There is overwhelming evidence linking the NLRP3 inflammasome and the IL-1 cytokines with the pathogenesis of CVDs."
|
|
Apr
8 |
Olatec’s CSO, Charles Dinarello MD, discusses dapansutrile, an oral NLRP3 inhibitor, as an optimal target to prevent and treated the inflammatory cytokine storm in COVID-19 patients, during a grand rounds featured presentation for Colorado University’s Department of Medicine.
See also CU News Release. |
|
Apr
7 |
We are pleased to report that The Lancet Rheumatology published our paper, "Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial" along with a third-party commentary entitled, "Dapansutrile: a new hope?". Olatec's publication presents the successful results of our clinical proof of concept trial for dapansutrile in acute gout. Acute gout was strategically selected as it is a prototypical NLRP3 mediated disease, validating the potential for our NLRP3 inhibitor in a broad spectrum of inflammatory diseases.
|
|
Feb
17 |
Olatec cited in the C&EN cover story entitled “Could an NLRP3 inhibitor be the one drug to conquer common diseases?”
|
|
Nov
11-12 |
At the world’s leading organization for rheumatology health professionals - Olatec presented its datasets demonstrating significant clinical antiinflammatory effect and clean safety profile with oral dapansutrile in the treatment of acute gout attacks in oral and poster presentations. The acceptance of these two abstracts by American College of Rheumatology (ACR) and Association of Rheumatology Professionals (ARP) for presentations at their 2019 Annual Meeting in Atlanta, Georgia provides further validation of the positive results in our first human Phase 2 trial of an oral NLRP3 inflammasome inhibitor. About ACR/ARP: since its beginnings over 80 years ago, today, ACR draws more than 16,000 attendees from more than 100 countries to its Annual Meeting each year. (In compliance with ACR’s disclaimer requirements, this news release is being made solely by Olatec).
|
|
Nov
1 |
Olatec’s fourth peer-reviewed publication and first publication on the benefits of dapansutrile in preclinical models of neurodegenerative disease, specifically in multiple sclerosis (MS), published in Frontiers Immunology. In this publication, “OLT1177 (dapansutrile), a selective NLRP3 inhibitor, ameliorates experimental autoimmune encephalomyelitis pathogenesis,” we show that oral treatment of dapansutrile – an NLRP3 inhibitor – delays and reduces disease progression in a mouse model of MS. These data provide justification of the potential clinical benefit of dapansutrile in MS patients. Frontiers Immunology ranks as the 5th most-cited publisher among the 20 largest publishers in 2019.
Link to publication, here. |
|
Oct
14 |
Charles Dinarello MD, co-CSO and Chairman of Olatec’s Scientific Advisory Board, presents “Treating Inflammation with IL-1 Blockade from Gout to Cancer”, in which he presents data on dapansutrile, at ITMAT’s 14th Annual International Symposium – Translational Targets and Precision Medicine: Taming Inflammation and Improving Resilience as We Age in Philadelphia, PA.
|
|
Oct
1 |
Carlo Marchetti, PhD, Director for Olatec’s Innovative Science Program in Dr. Charles Dinarello’s Laboratory, publishes a review entitled “The NLRP3 inflammasome as pharmacological target”, in the Journal of Cardiovascular Pharmacology, in which Olatec’s lead compound, dapansutrile, is referenced
Read More |
|
Oct
1 |
A review of Olatec’s lead compound, dapansutrile (lab code: OLT1177®), appears in the Journal of Cardiovascular Pharmacology publication entitled “Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes”co-authored by Leo F. Buckley, PharmD and Olatec Scientific Advisory Board Member, Peter Libby, MD.
Read More |
|
Sep
12 |
Olatec’s lead compound (OLT1177® dapansutrile) referenced in Nature Reviews Rheumatology publication by Charles Dinarello MD, CSO and Chairman of Olatec’s Scientific Advisory Board entitled, "The IL-1 family of cytokines and receptors in rheumatic diseases". The publication represents a further validation for dapansutrile in its acute gout flares and osteoarthritis clinical indications.
Read More |
|
Sep
9 |
The Company established Olatec Therapeutics BV, a wholly-owned subsidiary in the Netherlands (“Olatec BV”).
|
|
Sep
1 |
Olatec’s lead compound, dapansutrile, referenced in Journal of Cardiovascular Pharmacology publication entitled, "Drugs to Inhibit the NLRP3 Inflammasome: Not Always On Target"
Read More |
|
Sep
1 |
Olatec’s lead compound, dapansutrile, referenced in Journal of Cardiovascular Pharmacology publication entitled, "Cardiovascular Pharmacology of the NLRP3 Inflammasome"
Read More |
|
Sep
1 |
Olatec’s lead compound, dapansutrile, referenced in Journal of Cardiovascular Pharmacology publication entitled, "NLRP3 Inflammasome in Acute Myocardial Infarction"
Read More |
|
Aug
28 |
Olatec Therapeutics announces that dapansutrile met its primary and secondary endpoints in a Phase 2a trial (Study OLT1177-05) of patients with acute gout flares. This trial represents the first known selective NLRP3 inhibitor to demonstrate clinical benefit, safety and a reduction in systemic inflammation. Datasets on the clinical, inflammatory biomarker and safety outcomes will be presented this November at a prestigious conference.
|
|
Jun
13 |
Olatec’s lead compound, dapansutrile, referenced in Gout 1st Edition book entitled, "Gout: Chapter 17 Drugs in the Pipeline”, authored by Naomi Schlesinger, MD
Read More |
|
Jun
10 |
Olatec’s lead compound, dapansutrile, referenced in the Journal of Allergy and Clinical Immunology publication entitled, "A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: Therapeutic efficacy of proton pump inhibitors”
Read More |
|
Apr
29 |
Olatec’s lead compound, dapansutrile, referenced in Nature Reviews Immunology publication entitled, ”The NLRP3 inflammasome: molecular activation and regulation to therapeutics"
Read More |
|
Apr
23 |
Olatec’s lead compound, dapansutrile, referenced in EMBO Molecular Medicine publication entitled, ”Inflammasomes in neuroinflammatory and neurodegenerative diseases"
Read More |
|
Mar
31 |
Charles Dinarello MD, CSO and Chairman of Olatec’s Scientific Advisory Board presents select data on dapansutrile at the 10th Biannual Meeting of the International Society of Systemic Auto-Inflammatory Diseases (ISSAID) in Genoa, Italy.
|
|
Feb
12 |
Olatec’s lead compound, dapansutrile, referenced in Nature Cell Death & Disease publication entitled, “Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors”
Read More |
|
Feb
10 |
Timotheus L.Th.A. Jansen, MD PhD joins and becomes Chairman of the Olatec Clinical Advisory Board. Mr. Jansen has been contributing leading expertise in the design and conduct of Olatec’s human clinical trials in gout including serving as the principal investigator of the first clinical trial with dapansutrile for acute gout flares.
See Bio |
|
Feb
8 |
Olatec manuscript published in Journal of Cardiovascular Pharmacology entitled, "The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse”
Read More |
|
December
21 |
Olatec’s lead compound, dapansutrile, referenced in Cardiovascular Research publication entitled, “Innate immunity as a target for acute cardioprotection”
Read More |
|
November
21 |
Bob Fielding joins the Olatec Scientific Advisory Board. Mr. Fielding is contributing leading expertise in the design and conduct of Olatec’s pharmacology programs. Mr. Fielding has over 30 years experience in the pharmaceutical and biotech industries, including with formulation evaluation, preclinical pharmacokinetics/toxicokinetics, pharmacology and clinical pharmacokinetic studies for more than 30 products now approved or in clinical trials.
See Bio |
|
November
21 |
Steve Newhard joins the Olatec Scientific Advisory Board. Mr. Newhard has over 40 years of experience in the pharmaceutical and regulatory industry and is responsible for manufacturing of Olatec's Lead Compound at CMOs producing the active drug substance and drug product.
See Bio |
|
September
5-7 |
Charles Dinarello MD, CSO and Chairman of Olatec’s Scientific Advisory Board, and Leo Joosten PhD, Olatec SAB Member, presents select data on dapansutrile at the New Frontiers in Innate Immunity & Inflammation in Cluj Napoca, Romania.
|
|
August
31 |
Olatec referenced in American Journal of Physiology-Heart and Circulatory Physiology publication entitled, “Inflammasome, Pyroptosis, and Cytokines in Myocardial Ischemia-Reperfusion Injury”
Read More |
|
August
3 |
Olatec manuscript published in Arthritis Research & Therapy entitled, "NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis”
Read More |
|
July
20 |
Olatec’s lead compound, dapansutrile, referenced in Nature Reviews Drug Discovery publication entitled, "Targeting the NLRP3 inflammasome in inflammatory diseases”
Read More |
|
April
4 |
Olatec referenced in Nature Scientific Reports publication entitled,"Development of a characterised tool kit for the interrogation of NLRP3 inflammasome-dependent responses”
Read More |
|
March
1 |
Charles Dinarello MD, CSO and Chairman of Olatec’s Scientific Advisory Board, presents select data on dapansutrile at the European Crystal Network Workshop in Paris, France.
|
|
February
23 |
Olatec referenced in European Heart Journal, published on behalf of European Society of Cardiology, entitled, "Interleukin-1 blockade in cardiovascular diseases: a clinical update”
Read More |
|
January
29 |
Olatec’s research manuscript published in Proceedings of the National Academy of Sciences, entitled "OLT1177, a β‑sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation”.
Read More |
|
November
12 |
Stefano Toldo, PhD, Virginia Commonwealth University Assistant Professor, Department of Internal Medicine Division of Cardiology, presents poster, “Novel NLRP3 Inflammasome Inhibitor OLT1177 Reduces Infarct Size in a Mouse Model of Myocardial Ischemia Reperfusion Injury” at the AHA conference in Anaheim, CA
|
|
November
16 |
Olatec referenced in Nature Reviews Cardiology entitled, "The NLRP3 inflammasome in acute myocardial infarction”
|
|
October
11 |
Olatec referenced in Nature Biotechnology entitled, “Novartis trial validates inflammasome as chronic disease driver”
|
|
June
14 |
Carlo Marchetti, PhD, Director for Olatec’s Innovative Science Program in Dr. Charles Dinarello’s Laboratory, presents, “The Human Safe NLRP3 Inflammasome Inhibitor OLT1177 Suppresses Joint Inflammation in Murine Models of Experimental Arthritis” at EULAR conference in Madrid, Spain
|
|
April
21 |
Carlo Marchetti, PhD, Director for Olatec’s Innovative Science Program in Dr. Charles Dinarello’s Laboratory, presents poster, “The Novel and Safe Pharmaceutical Compound OLT1177 Reduces Inflammation by Preventing Activation of the NLRP3 inflammasome” at AAP/ASCI/APSA Meeting in Chicago, IL
|
|
March
19 |
Antonio Abbate, MD, PhD joins the Olatec Scientific Advisory Board. Dr. Abbate is a prominent leader in the field of cardiovascular disease
|
|
November
27 |
Franz Hefti, PhD joins the Olatec Scientific Advisory Board. Dr. Hefti is a prominent leader in the development of neurodegenerative therapeutics and an experienced biotech CEO
|